10 completed, 2 unknown, 1 withdrawn. 13 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 10, Unknown 2, Withdrawn 1 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 3 | Completed 3 |
Follow Dysphonia: new trials by email Literature Review of Dysphonia trials Research Report on Dysphonia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Laryngeal Vibro-tactile Stimulation as a Non-invasive Symptomatic Treatment for Spasmodic Dysphonia vibro-tactile stimulation (VTS) - Adductor Spasmodic Dysphonia, Abductor Spastic Dysphonia | Phase 2 | Withdrawn | University of Minnesota | 2026-08-01 | 2025-05-16 | |
| The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia Dexamethasone, Normal saline - Voice Change, Hypocalcemia | Phase 2 | Unknown | Tseung Kwan O Hospital, Hong Kong | 100 | 2024-07-01 | 2024-07-09 |
| Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia Vibro-tactile stimulation - Spasmodic Dysphonia, Laryngeal Dystonia | Phase 1 / Phase 2 | Completed | University of Minnesota | 40 | 2023-11-21 | 2026-07-15 |
| DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia DaxibotulinumtoxinA - Adductor Spasmodic Dysphonia, Voice Disorders | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 22 | 2023-10-13 | 2026-05-18 |
| Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia Zinc gluconate supplement, Botulinum toxin type A - Spasmodic Dysphonia | Phase 1 / Phase 2 | Completed | University of Florida | 32 | 2023-08-01 | 2026-07-27 |
| A Phase 2 Trial of Deep Brain Stimulation for Spasmodic Dysphonia DBS ON, DBS OFF - Spasmodic Dysphonia | Phase 2 | Unknown | University of British Columbia | 16 | 2023-01-30 | 2022-11-01 |
| Firdapse for Post-BOTOX Vocal Weakness Amifampridine - Vocal Weakness(Post-BOTOX Injection) | Phase 2 | Completed | Augusta University | 18 | 2021-10-28 | 2025-10-03 |
| Spasmodic Dysphonia Pain Lidocaine, Vibrating wand - Spasmodic Dysphonia | Phase 2 / Phase 3 | Completed | Mayo Clinic | 32 | 2021-08-01 | 2024-05-23 |
| A Study of Local Administration of Autologous Mesenchymal Stromal Cells in Dysphonic Patients With Vocal Fold Scarring MSC-KI-PL-204 - Hoarseness, Dysphonia | Phase 1 / Phase 2 | Completed | Karolinska University Hospital | 9 | 2021-03-01 | 2026-01-27 |
| Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor Sodium Oxybate - Spasmodic Dysphonia, Voice Tremor | Phase 2 / Phase 3 | Completed | Kristina Simonyan | 117 | 2018-01-22 | 2025-12-30 |
| Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges Type 2 Thyroplasty using Titanium Bridges - Adductor Spasmodic Dysphonia | Phase 2 / Phase 3 | Completed | Kumamoto University | 20 | 2015-07-27 | 2018-05-02 |
| Effects of Octanoic Acid for Treatment of Essential Voice Tremor Octanoic acid, Inactive capsule - Essential Voice Tremor, Vocal Tremor | Phase 1 / Phase 2 | Completed | Syracuse University | 17 | 2013-07-01 | 2018-08-20 |
| Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response Sodium oxybate - Spasmodic Dysphonia, Voice Tremor | Phase 2 | Completed | Kristina Simonyan | 53 | 2012-07-01 | 2017-11-22 |
Hoarseness (2) · Tremor (2) · Voice Disorders (2) · Aphonia (1) · Dystonia (1) · Essential Tremor (1) · Hypocalcemia (1) · Hypoparathyroidism (1) · Pain (1) · Vocal Cord Paralysis (1)
Laryngeal Diseases (13) · Nervous System Diseases (13) · Neurologic Manifestations (13) · Otorhinolaryngologic Diseases (13) · Pathological Conditions, Signs and Symptoms (13) · Respiratory Tract Diseases (13) · Signs and Symptoms (13) · Voice Disorders (11) · Dyskinesias (2) · Respiration Disorders (2) · Signs and Symptoms, Respiratory (2) · Calcium Metabolism Disorders (1) · Central Nervous System Diseases (1) · Cranial Nerve Diseases (1) · Endocrine System Diseases (1)
Botulinum Toxins, Type A (2) · Sodium Oxybate (2) · Amifampridine (1) · Dexamethasone (1) · Ethanol (1) · Lidocaine (1) · Saline Solution (1) · gluconic acid (1) · octanoic acid (1)
Kristina Simonyan (2) · University of Minnesota (2) · Augusta University (1) · Karolinska University Hospital (1) · Kumamoto University (1) · Mayo Clinic (1) · Syracuse University (1) · Tseung Kwan O Hospital, Hong Kong (1) · University of British Columbia (1) · University of California, San Francisco (1) · University of Florida (1)
United States (9) · Canada (1) · Hong Kong (1) · Japan (1) · Sweden (1)
Kristina Simonyan, MD, PhD (2) · Christopher R Honey, MD (1) · Clark Rosen, MD (1) · David Lott, MD (1) · Jason YK Chan, MBBS (1) · Juergen Konczak, PhD (1) · Michael H Rivner, MD (1) · Neil Chheda (1) · Patric Scicluna, Clin Research Manager (1) · Soren Y Lowell, PhD (1) · Tetsuji Sanuki, MD,PhD (1)
PMID 14718713, PMID 15210907, PMID 21594724, PMID 22454323, PMID 23408867, PMID 25929664, PMID 27808415, PMID 30382161, PMID 37448353, PMID 40850907, PMID 42002761
R01DC012545 (2), 2019 (1), R03DC012429 (1)